DECT for Differentiating Intracerebral Hemorrhage From Contrast Extravasation

Launched by UNIVERSITY OF MANITOBA · Jan 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Dual-Energy Computed Tomography (DECT) to see if it can help doctors better distinguish between two conditions in patients who have had a stroke: intracranial hemorrhage (bleeding in the brain) and contrast extravasation (a leak of the dye used in imaging). The trial is looking at whether DECT is more accurate than the standard imaging method, Single-Energy CT (SECT), in identifying these conditions after stroke treatments like thrombolysis (a medication to dissolve blood clots) or thrombectomy (a procedure to remove clots).

To participate in this study, patients must be at least 18 years old and have experienced an acute ischemic stroke, meaning a blockage in a blood vessel that supplies blood to the brain. They should be candidates for either thrombolysis or endovascular thrombectomy. Participants will undergo both the standard SECT and the DECT imaging after their treatment, with follow-up imaging scheduled 72 hours later to confirm the results. This trial aims to see if using DECT can lead to improved care for stroke patients by providing clearer information about their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients greater than or equal to 18 years of age presenting with acute ischemic stroke (AIS) that are candidates for 1) thrombolysis (tPA) and/or 2) endovascular thrombectomy (EVT)
• Exclusion Criteria:
• * Patients who are not candidates for tPA:
• • Intracerebral Hemorrhage on CT Ischemic Stroke within 3 months, Severe head trauma within 3 months Acute head trauma GI Malignancy or BI bleed within 21 days Coagulopathy (Platelets \<100,000/mm3, INR \>1.7, aPTT \>40s, PT\>15s) Anticoagulation (thrombin inhibitors, factor Xa inhibitors, low-molecular weight heparin) History of intracranial hemorrhage Intra-axial neoplasm Infective endocarditis Aortic Arch Dissection Patient receiving IV aspirin Patient receiving IV abciximab
• * Patients who are not candidates for EVT:
• • No large vessel occlusion on CT angiogram Baseline Modified Rankin Scale \>3 No significant perfusion mismatch